Table 3.

Prevalence of the possible HFE genotypes in each subject group

	Normal control (n=493)	IHD control (n=427)	MI survivor (n=828)	Normal control v IHD control OR (95% CI)	Normal control v MI survivor OR (95% CI)
Wild type	268 (54.4%)	249 (58.3%)	468 (56.5%)	1.17 (0.90 to 1.5)	1.14 (0.87 to 1.5)
H63D homozygote	10 (2.0%)	9 (2.1%)	23 (2.8%)	1.02 (0.41 to 2.6)	1.22 (0.51 to 2.9)
H63D heterozygote	115 (23.3%)	98 (23.0%)	198 (23.9%)	0.97 (0.71 to 1.3)	1.04 (0.76 to 1.4)
Compound heterozygote	15 (3.0%)	7 (1.6%)	31 (3.7%)	0.53 (0.21 to 1.3)	0.87 (0.42 to 1.8)
C282Y homozygote	5 (1.0%)	3 (0.7%)	7 (0.8%)	0.71 (0.17 to 3.0)	1.20 (0.23 to 6.2)
C282Y heterozygote	80 (16.2%)	61 (14.3%)	101 (12.2%)	0.88 (0.61 to 1.3)	0.70 (0.48 to 1.04)

None of the genotype groups achieved significance.

HFE, haemochromatosis gene.